https://www.selleckchem.com/pr....oducts/pexidartinib-
028 and P=0.032, respectively) compared to Group 1. Dogs in Group 2b were more likely to have adverse effects associated with treatment than dogs in Group 1 (P=0.004). There were no significant differences in lesion type, distribution, rates of remission, recurrence or corticosteroid dosage between groups. Dogs with PF and concurrent vasculitis took longer to achieve remission and were more likely to have systemic signs of illness or adverse effects associated with treatment than dogs with PF without concurrent vasculopathi
Beğen
Yorum Yap
Paylaş
